Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800 Joseph Schoepfer, Paul A. Brough, et al. Mol Cancer Ther 2010;9:906-919
Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800 Thorsten Stuhmer,Manik Chatterjee,et al. British Journal of Haematology 2009;147:319–327
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.